PBM Prescription Validation Requests Rose Nearly 20% in 2022!
Prescription Validation Requests (also known as claim reviews) are becoming a more frequent occurrence with many PBMs. In 2022, PAAS saw an 18% increase year over year. Some of the reasons these claims get flagged include:
- High dollar claims
- High quantity to days’ supply ratios
- NDC package size mismatched to quantity billed
While these requests are a nuisance, they can work to the pharmacy’s benefit. With the PBM looking at the claim prospectively (before payment is received), pharmacies can avoid incorrectly refilling medication if an error is detected. Conversely, if a pharmacy is not prompted to correct an error (when one exists) and the claim is refilled over the course of a year, the financial recoupments can be much greater upon audit. The frustration comes in when these claim reviews are repetitious, and false positives (i.e., no billing errors) – creating work for the pharmacy without the need for claim correction.
Below is a chart of the various PBMs conducting these prospective reviews and the details/nuances associated with each. OptumRx/EXL® makes up the majority of these pre-claim reviews that members report to PAAS. OptumRx defines the Prescription Validation Request (PVR) in their pharmacy manual as follows:
Administrator conducts limited scope prescription validation reviews for quality assurance purposes (“PVRs”), which are distinct from and are not considered audits. PVRs are utilized to verify the accuracy and validity of prescription claim submissions. Claims are monitored daily for appropriateness and potential billing errors and selected for review prior to payment. Network Pharmacy Providers are typically contacted via fax or email and asked to provide photocopies of specific documents and records related to its claims submitted to Administrator. (Unusual quantity and days’ supply combination) (Unusual quantity and days’ supply, incorrect DAW code) While PBMs have fancy names for these requests, make no mistake: if it looks like an audit, you must submit documentation like an audit, and you get results (and recoupments) like an audit, it is an audit! PAAS Tips:
PBM
Title of Request
Days to Respond
Targeted Claims
Caremark®
Concurrent Claim Review
3
Compounds, non-FDA approved products, injections
Express Scripts®
Claims for Investigative Review
5
CII’s
Humana®
Pharmacy Claim Validation Request
3 business
Potentially misbilled claims
MagellanRx/Conduent
Claim Check verification review
7
High dollar (Emgality ®, insulin)
MedImpact
Pre-pay Claim Review
3 business
Potential billing errors
OptumRx/EXL®
Validation Request
14 business
High dollar (Humira®, Enbrel®, insulin, inhalers)
Prime Therapeutics
Initial Documentation Request
2
High-dose insulin
- Understanding Biologic Substitutions – New Tool Available! - November 12, 2024
- FDA Proposed Guidance for Biosimilar Updates - October 23, 2024
- Avoid OptumRx® Double Chargeback Pitfalls – Review Your Days’ Supply - October 1, 2024